RXRX vs SEPN

Recursion Pharmaceuticals, Inc. vs Septerna, Inc. — Valuation Comparison 2026

RXRX

Biotechnology
Recursion Pharmaceuticals, Inc.
Quality
6.5
out of 10
Value Trap
37
LOW
Price
$3.44
Last close
Models
9/13
Active
VS

SEPN

Biotechnology
Septerna, Inc.
Quality
7.0
out of 10
Value Trap
12
SAFE
Price
$31.05
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType RXRX Fair ValueRXRX Upside SEPN Fair ValueSEPN Upside
Bayesian DCF Intrinsic $1.52 -55.8% $15.59 -49.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.99 -42.2% $4.39 -85.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RXRX vs SEPN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RXRX vs SEPN — Which Stock Is More Undervalued?

SEPN scores higher with a 7.0/10 quality rating vs RXRX's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Recursion Pharmaceuticals, Inc. (RXRX) and Septerna, Inc. (SEPN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RXRX currently trades at $3.44 with a QOC of 6.5/10, while SEPN trades at $31.05 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).